Pipeline

L.E.A.F. Pharmaceuticals currently has several new products in development, targeting solid tumors.  Good Manufacturing Practice (GMP) campaign underway for lead products: LEAF-1401, LEAF-1701 and LEAF-1404 (generic liposomal doxorubicin).

New Products in Development